Vonjo

Approved Uses

Vonjo is used to treat adults with intermediate or high-risk myelofibrosis, a rare type of bone marrow cancer. It is specifically indicated for patients who have severe thrombocytopenia, which is a blood platelet count of less than 50,000/µL.

The medication is approved for use in patients with the following conditions:

• Primary myelofibrosis: A condition where the bone marrow is replaced by scar tissue.
• Post-polycythemia vera myelofibrosis: A form of the disease that develops in people who previously had polycythemia vera.
• Post-essential thrombocythemia myelofibrosis: A form of the disease that develops in people who previously had essential thrombocythemia.

Clinical Application

In patients with myelofibrosis, the bone marrow cannot produce enough healthy blood cells, often leading to an enlarged spleen and symptoms such as fatigue, night sweats, and bone pain. Vonjo is used to help reduce the size of the spleen and manage these symptoms. It is particularly useful for patients whose low platelet counts might make other similar medications unsuitable.

This drug received accelerated approval from the FDA based on clinical trials showing a reduction in spleen volume. Continued approval for this use may depend on the results of ongoing studies to confirm its clinical benefit.

Targeting Specific Enzymes

Vonjo is a type of medication known as a kinase inhibitor. It works by blocking the activity of certain proteins in the body, specifically Janus kinase 2 (JAK2) and interleukin-1 receptor-associated kinase 1 (IRAK1).

In people with myelofibrosis, these proteins are often overactive. This overactivity sends constant signals to the bone marrow to produce too many blood cells. Over time, this process leads to inflammation and the development of scar tissue (fibrosis) within the bone marrow. This scarring makes it difficult for the marrow to produce healthy blood cells normally.

How It Affects the Body

By interfering with these signaling pathways, Vonjo helps to regulate the production of blood cells and reduce inflammation. This can lead to several effects:

• Reduction in spleen size: Myelofibrosis often causes the spleen to enlarge as it tries to take over blood cell production from the scarred bone marrow.
• Control of symptoms: Blocking these pathways helps reduce the inflammatory signals that contribute to many symptoms of the condition.

Vonjo is designed to target these pathways while remaining compatible with low platelet levels, which are the blood cells responsible for clotting.

Common Side Effects

The most frequently reported side effects of Vonjo include:

• Diarrhea
• Nausea and vomiting
• Swelling in the legs, ankles, or feet (peripheral edema)
• Low red blood cell counts (anemia)
• Low platelet counts (thrombocytopenia)

Serious Side Effects

While less common, Vonjo can cause serious health problems. Seek medical attention immediately if you experience symptoms of the following:

• Severe Bleeding: This may include unusual bruising, blood in the stool or urine, or coughing up blood.
• Heart Rhythm Problems: Symptoms may include dizziness, lightheadedness, or a racing heartbeat.
• Cardiovascular Events: An increased risk of major events such as heart attack or stroke.
• Blood Clots: Pain, swelling, or redness in the legs, or sudden shortness of breath.
• Infections: Fever, chills, or other signs of a new or worsening infection.
• Secondary Cancers: An increased risk of developing other types of cancer, such as certain skin cancers.

Bleeding Risks

Serious and sometimes fatal bleeding (hemorrhage) can occur during treatment. Healthcare providers typically monitor for signs of bleeding and may need to pause or stop the medication if bleeding becomes severe. Patients with low platelet counts or those taking blood thinners may be at a higher risk.

Diarrhea

Diarrhea is a common side effect and can lead to dehydration if not managed. It is often addressed with anti-diarrheal medications, increased fluid intake, or changes to the Vonjo dosage. Severe cases may require interrupting treatment.

Heart Rhythm Changes

Vonjo can cause a heart rhythm problem known as QT prolongation. This condition can lead to a serious or life-threatening irregular heartbeat. Monitoring usually involves regular electrocardiograms (EKGs) and blood tests to check electrolyte levels, such as potassium and magnesium.

Cardiovascular Events and Blood Clots

There is an increased risk of major cardiovascular events, such as heart attack or stroke, particularly in people with existing risk factors or a history of smoking. Additionally, blood clots in the veins of the legs (deep vein thrombosis) or the lungs (pulmonary embolism) have been reported in patients taking this class of medication.

Infection and Cancer Risks

Treatment may increase the risk of developing serious bacterial, fungal, or viral infections. There is also a potential risk of developing other types of cancer, such as lymphoma or non-melanoma skin cancer, while taking JAK inhibitors like Vonjo.

Drug Interactions

Vonjo can interact with other medications, particularly those that affect liver enzymes (CYP3A4). Using Vonjo with certain drugs may increase the level of the medication in the body or decrease its effectiveness. It is important to review all current medications and supplements with a healthcare provider.

Pregnancy

There are no adequate studies on the use of Vonjo in pregnant women to determine drug-associated risks. However, based on findings from animal studies, this medication may cause harm to a developing fetus. It is important to discuss the potential risks and benefits with a healthcare provider if you are pregnant or planning to become pregnant.

For individuals of reproductive potential, healthcare providers typically recommend the following:

• A pregnancy test should be performed before starting treatment to confirm you are not pregnant.
• Effective birth control (contraception) should be used during treatment and for at least 2 weeks after the final dose.

Breastfeeding

It is not known if Vonjo passes into human breast milk or how it might affect a nursing infant. Because of the potential for serious adverse reactions in a breastfed child, it is advised that individuals do not breastfeed while taking this medication and for at least 2 weeks after the last dose.

Fertility

Based on animal studies, Vonjo may impair fertility in both females and males. If you have concerns about future fertility, talk to your healthcare provider before starting treatment.

Available Forms

Vonjo is available as a capsule for oral administration. The capsules are designed to be swallowed whole and should not be opened, crushed, or chewed.

FDA Approval History

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Vonjo on February 28, 2022. The approval was based on clinical trial data showing the drug's ability to reduce spleen volume in patients with specific forms of bone marrow disorders.

Approved Indications

Vonjo is approved for use in adults with intermediate or high-risk primary or secondary myelofibrosis (including post-polycythemia vera or post-essential thrombocythemia myelofibrosis) who have a platelet count below 50 × 10^9/L.

Regulatory Status and Requirements

As part of the accelerated approval process, the FDA requires further clinical trials to confirm the drug's clinical benefit. The continued approval of Vonjo for this specific use may depend on the results of these ongoing studies.

Currently, Vonjo does not have a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) program. However, the FDA-approved labeling includes warnings regarding serious risks, such as severe bleeding (hemorrhage), heart rhythm abnormalities (prolonged QT interval), and major adverse cardiovascular events.

Insurance and Pharmacy Factors

The price of Vonjo is influenced by several factors, including your specific health insurance plan. Your out-of-pocket costs will depend on your plan's deductible, copayment, or coinsurance requirements. Because Vonjo is a specialty medication, it is typically available only through specialty pharmacies rather than standard retail pharmacies.

Financial Assistance

There are several resources available that may help reduce the cost of treatment for eligible patients:

• Manufacturer Assistance: Programs may be available to help patients with commercial insurance lower their out-of-pocket expenses through copay cards or similar support.
• Patient Assistance Programs: These programs are often designed for individuals who are uninsured or underinsured to help them access necessary medications.
• Foundation Support: Some independent charitable organizations provide financial grants to help cover the costs of medications for myelofibrosis and other rare conditions.

Patients are encouraged to contact their insurance provider or a specialty pharmacy to determine their specific coverage and to learn about available support programs.